抗PLA2R1及抗CysR抗体、结构域识别与利妥昔单抗疗效在膜性肾病中的前瞻性队列研究
结果显示基线抗PLA2R1和抗CysR抗体滴度较低与缓解概率较高相关,而抗CTLD抗体及多结构域识别与结局无关。
要点
- 基线抗PLA2R1和抗CysR抗体滴度较低与利妥昔单抗后缓解概率较高独立相关。
- 抗CTLD1、CTLD7和CTLD8抗体及多结构域识别与缓解无关。
- 抗PLA2R1与抗CysR滴度高度相关,检测选择可基于可行性和成本。
核心结论
- 在PLA2R1相关膜性肾病中,抗PLA2R1和抗CysR抗体相似地预测利妥昔单抗疗效,独立于PLA2R1结构域识别。
- 评估抗CTLD抗体似乎没有必要。
主要发现
- 中位随访37.1个月(IQR 20.3-56.9),71例(62.8%)达到完全或部分缓解。
- 基线抗PLA2R1抗体滴度较低与缓解概率较高相关(HR 0.997 [95% CI 0.996-0.999],P=0.002)。
- 基线抗CysR抗体滴度较低与缓解概率较高相关(HR 0.996 [95% CI 0.993-0.998],P=0.001)。
- 女性、较低蛋白尿和较低血清肌酐水平也与缓解概率较高相关(P<0.05)。
- 抗CTLD抗体与结局无关;6和12个月时,缓解患者的抗PLA2R1和抗CysR抗体滴度下降幅度大于未缓解者(P<0.05)。
关键数值与推荐
- 完全缓解定义为蛋白尿<0.3g/24h;部分缓解定义为蛋白尿≥0.3g/24h且<3.0g/24h并较基线下降>50%。
- 所有患者均检出抗CysR抗体;62例(54.9%)为多结构域识别者。
- 基线、6个月和12个月时抗PLA2R1与抗CysR抗体滴度强相关(P<0.001,r分别为0.934、0.964、0.944)。
临床怎么用
- 临床可监测抗PLA2R1或抗CysR抗体滴度以评估利妥昔单抗治疗后的缓解概率。
- 抗PLA2R1与抗CysR检测选择可由可行性和成本决定,无需常规检测抗CTLD抗体。
局限性
- 观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Proteinuria and anti-phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes. EXPOSURE: Rituximab. OUTCOME: Complete (proteinuria<0.3g/24h) or partial (proteinuria≥0.3g/24h and<3.0g/24h with>50% reduction vs basal) NS remission. ANALYTICAL APPROACH: Univariable and multivariable Cox regression analyses. RESULTS: All patients had anti-CysR antibodies; 62 (54.9%) were multidomain recognizers. Anti-PLA2R1 and anti-CysR antibody titers were strongly correlated at baseline (P<0.001, r=0.934), 6 months (P<0.001, r=0.964), and 12 months (P<0.001, r=0.944). During a median follow-up of 37.1 (IQR, 20.3-56.9) months, 71 patients (62.8%) achieved either complete or partial remission of their NS. Lower baseline anti-PLA2R1 (HR, 0.997 [95% CI, 0.996-0.999], P=0.002) and anti-CysR [HR, 0.996 [95% CI, 0.993-0.998], P=0.001) titers were associated with a higher probability of remission, along with female sex, lower proteinuria, and lower serum creatinine levels (P<0.05 for all comparisons). Anti-CTLD antibodies were not associated with outcomes. At 6 and 12 months, compared to baseline, anti-PLA2R1 and anti-CysR antibody titers decreased more in patients progressing to partial or complete remission than in those without remission (P<0.05 for all comparisons). LIMITATIONS: Observational design. CONCLUSIONS: In PLA2R1-related MN, anti-PLA2R1 and anti-CysR antibodies similarly predict rituximab efficacy independent of PLA2R1 domain recognition. The choice between these tests should be dictated by feasibility and costs. Evaluating anti-CTLD antibodies appears unnecessary. PLAIN-LANGUAGE SUMMARY: Primary membranous nephropathy (MN), a leading cause of nephrotic syndrome (NS) in adults, is an autoimmune disease caused by autoantibodies binding to the podocyte antigen phospholipase A2 receptor 1 (PLA2R1). We assessed whether the effects of anti-CD20 cytolytic therapy with the monoclonal antibody rituximab are associated with detection rates and levels of anti-PLA2R1 antibodies and antibodies against PLA2R1 domains such as cysteine-rich (CysR), and C-type lectin 1, 7, and 8 (CTLD1, 7, and 8), in patients with PLA2R1-related MN and persistent NS. The probability of rituximab-induced complete or partial NS remission was associated with baseline anti-PLA2R1 and anti-CysR antibody titers, but not with anti-CTLD1, 7 and 8 antibodies or multidomain recognition. Integrated evaluation of anti-PLA2R1 or anti-CysR antibodies with proteinuria and kidney function may play a role in monitoring the effects of rituximab in patients with PLA2R1-related NS and MN.
引用
- Ruggenenti P, Reinhard L, Ruggiero B, et al. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study. Am J Kidney Dis. 2023. PMID: 38151224. doi:10.1053/j.ajkd.2023.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。